PIC Therapeutics is a biotechnology company focused on fundamentally changing how cancer is treated by developing a new generation of therapeutics based on the modulation of RNA translation
PIC Therapeutics’ precision-based therapeutics target the “master switch” of cancer signalling pathways, selectively blocking oncogene protein production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA translation.
PIC Therapeutics’ selective approach has the potential to simultaneously modulate multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics.
CEO Katherine Bowdish
Advent Contact Alan Walts